Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01353222 · ClinicalTrials.gov registry record · Phase 2
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Phase 2 study, sponsored by Dendreon.
- Terminated
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT01353222: Clinical Trial Phase 2 study, sponsored by Dendreon.
NCT01353222 is a Phase 2 study that was terminated before completion, run by Dendreon. The registered enrollment target is 142 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01353222, a Phase 2 study, was terminated before completion, sponsored by Dendreon.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
This study was conducted to examine survival, disease-free survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.
Primary Outcome
Overall survival is defined as the time from randomization to death due to any cause. \*This study was terminated early due to administrative reasons.
Interventions
- OTHER Standard of Care
- BIOLOGICAL DN24-02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Why NCT01353222 stopped before completion
NCT01353222 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT01353222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01353222 about?
NCT01353222 is a clinical study titled "DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma". This study was conducted to examine survival, disease-free survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.
What is the current status of trial NCT01353222?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2011-06. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01353222?
The interventions under investigation include: Standard of Care (OTHER), DN24-02 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01353222?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01353222's enrollment target sits among peer trials
142 507th of 2000 higher than 1,491 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia